Detailing Translational Development & Clinical Dose Escalation of JK06: A 5T4-Directed Biparatopic ADC

• Detailing clinical dose escalation activity of biparatopic ADC JK06 across efficacy, safety and PK data
• Contrasting emerging JK06 clinical profile versus anticipated results from the preclinical characterisation
• Explaining the potential of quadrivalent biparatopic ADCs to deliver differentiated clinical performance versus classical ADC design

Speakers:

Sam Murphy

Chief Executive Officer

Salubris Bio